These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 37003447)
1. Multimodal comparisons of QSM and PET in neurodegeneration and aging. Cogswell PM; Fan AP Neuroimage; 2023 Jun; 273():120068. PubMed ID: 37003447 [TBL] [Abstract][Full Text] [Related]
3. Quantitative susceptibility mapping in β-Amyloid PET-stratified patients with dementia and healthy controls - A hybrid PET/MRI study. Tiepolt S; Rullmann M; Jochimsen TH; Gertz HJ; Schroeter ML; Patt M; Sabri O; Barthel H Eur J Radiol; 2020 Oct; 131():109243. PubMed ID: 32916411 [TBL] [Abstract][Full Text] [Related]
4. Simultaneous quantitative susceptibility mapping and Flutemetamol-PET suggests local correlation of iron and β-amyloid as an indicator of cognitive performance at high age. van Bergen JMG; Li X; Quevenco FC; Gietl AF; Treyer V; Meyer R; Buck A; Kaufmann PA; Nitsch RM; van Zijl PCM; Hock C; Unschuld PG Neuroimage; 2018 Jul; 174():308-316. PubMed ID: 29548847 [TBL] [Abstract][Full Text] [Related]
5. Quantitative Susceptibility Mapping of Brain Iron and β-Amyloid in MRI and PET Relating to Cognitive Performance in Cognitively Normal Older Adults. Chen L; Soldan A; Oishi K; Faria A; Zhu Y; Albert M; van Zijl PCM; Li X Radiology; 2021 Feb; 298(2):353-362. PubMed ID: 33231528 [TBL] [Abstract][Full Text] [Related]
6. MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Bilgic B; Pfefferbaum A; Rohlfing T; Sullivan EV; Adalsteinsson E Neuroimage; 2012 Feb; 59(3):2625-35. PubMed ID: 21925274 [TBL] [Abstract][Full Text] [Related]
7. APART-QSM: An improved sub-voxel quantitative susceptibility mapping for susceptibility source separation using an iterative data fitting method. Li Z; Feng R; Liu Q; Feng J; Lao G; Zhang M; Li J; Zhang Y; Wei H Neuroimage; 2023 Jul; 274():120148. PubMed ID: 37127191 [TBL] [Abstract][Full Text] [Related]
9. Ironsmith: An automated pipeline for QSM-based data analyses. Zachariou V; Bauer CE; Powell DK; Gold BT Neuroimage; 2022 Apr; 249():118835. PubMed ID: 34936923 [TBL] [Abstract][Full Text] [Related]
10. Quantitative susceptibility mapping as an imaging biomarker for Alzheimer's disease: The expectations and limitations. Uchida Y; Kan H; Sakurai K; Oishi K; Matsukawa N Front Neurosci; 2022; 16():938092. PubMed ID: 35992906 [TBL] [Abstract][Full Text] [Related]
11. High-resolution characterisation of the aging brain using simultaneous quantitative susceptibility mapping (QSM) and R2* measurements at 7T. Betts MJ; Acosta-Cabronero J; Cardenas-Blanco A; Nestor PJ; Düzel E Neuroimage; 2016 Sep; 138():43-63. PubMed ID: 27181761 [TBL] [Abstract][Full Text] [Related]
12. Quantitative Susceptibility Mapping of Amyloid-β Aggregates in Alzheimer's Disease with 7T MR. Tiepolt S; Schäfer A; Rullmann M; Roggenhofer E; ; Gertz HJ; Schroeter ML; Patt M; Bazin PL; Jochimsen TH; Turner R; Sabri O; Barthel H J Alzheimers Dis; 2018; 64(2):393-404. PubMed ID: 29865069 [TBL] [Abstract][Full Text] [Related]
13. Microglial activation, tau and amyloid deposition in TREM2 p.R47H carriers and mild cognitive impairment patients: a multi-modal/multi-tracer PET/MRI imaging study with influenza vaccine immune challenge. Cousins O; Schubert JJ; Chandra A; Veronese M; Valkimadi P; Creese B; Khan Z; Arathimos R; Hampshire A; Rosenzweig I; Ballard C; Corbett A; Aasland D; Velayudhan L; O'Neill M; Collier D; Awais R; Sander K; Årstad E; Howes O; Turkheimer F; Hodges A J Neuroinflammation; 2023 Nov; 20(1):272. PubMed ID: 37990275 [TBL] [Abstract][Full Text] [Related]
14. Assessment of the In Vivo Relationship Between Cerebral Hypometabolism, Tau Deposition, TSPO Expression, and Synaptic Density in a Tauopathy Mouse Model: a Multi-tracer PET Study. Endepols H; Anglada-Huguet M; Mandelkow E; Schmidt Y; Krapf P; Zlatopolskiy BD; Neumaier B; Mandelkow EM; Drzezga A Mol Neurobiol; 2022 Jun; 59(6):3402-3413. PubMed ID: 35312967 [TBL] [Abstract][Full Text] [Related]
15. Comparison of quantitative susceptibility mapping methods for iron-sensitive susceptibility imaging at 7T: An evaluation in healthy subjects and patients with Huntington's disease. Yao J; Morrison MA; Jakary A; Avadiappan S; Chen Y; Luitjens J; Glueck J; Driscoll T; Geschwind MD; Nelson AB; Villanueva-Meyer JE; Hess CP; Lupo JM Neuroimage; 2023 Jan; 265():119788. PubMed ID: 36476567 [TBL] [Abstract][Full Text] [Related]
16. In Vivo MRI Mapping of Brain Iron Deposition across the Adult Lifespan. Acosta-Cabronero J; Betts MJ; Cardenas-Blanco A; Yang S; Nestor PJ J Neurosci; 2016 Jan; 36(2):364-74. PubMed ID: 26758829 [TBL] [Abstract][Full Text] [Related]
17. Developmental trajectory of magnetic susceptibility in the healthy rhesus macaque brain. Wu J; Peng S; Zhang Y; Pan B; Chen H; Hu X; Gong NJ NMR Biomed; 2022 Sep; 35(9):e4750. PubMed ID: 35474524 [TBL] [Abstract][Full Text] [Related]
18. Glial activation is moderated by sex in response to amyloidosis but not to tau pathology in mouse models of neurodegenerative diseases. Biechele G; Franzmeier N; Blume T; Ewers M; Luque JM; Eckenweber F; Sacher C; Beyer L; Ruch-Rubinstein F; Lindner S; Gildehaus FJ; von Ungern-Sternberg B; Cumming P; Bartenstein P; Rominger A; Höglinger GU; Herms J; Brendel M J Neuroinflammation; 2020 Dec; 17(1):374. PubMed ID: 33317543 [TBL] [Abstract][Full Text] [Related]
19. Quantitative susceptibility mapping of brain iron in healthy aging and cognition. Madden DJ; Merenstein JL Neuroimage; 2023 Nov; 282():120401. PubMed ID: 37802405 [TBL] [Abstract][Full Text] [Related]
20. Prediction of amyloid positron emission tomography positivity using multiple regression analysis of quantitative susceptibility mapping. Ikebe Y; Sato R; Amemiya T; Udo N; Matsushima M; Yabe I; Yamaguchi A; Sasaki M; Harada M; Matsukawa N; Kawata Y; Bito Y; Shirai T; Ochi H; Kudo K Magn Reson Imaging; 2023 Nov; 103():192-197. PubMed ID: 37558171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]